Reducing Agents

09/01/1991 - "This article is intended to provide the reader with a comprehensive list of the available afterload-reducing agents, to review the relevant studies of these drugs in humans and dogs with heart failure, and to provide guidelines for their use in commonly encountered clinical situations."
07/01/2009 - "Because no clinical data with specific heart-rate-reducing agents are available in heart failure patients until now, the prospective significance of I(f)-channel inhibition can only be speculated on. "
04/01/1984 - "To examine its potential value as an afterload reducing agent in congestive heart failure 11 patients were studied. "
01/30/1987 - "It should be useful in the treatment of hypertension, and, considering its pattern of cardiac actions, perhaps also as an after-load-reducing agent for the treatment of heart failure. "
01/01/2014 - "Ivabradine is a pure heart rate-reducing agent that has no effect on blood pressure and contractility, and can reverse left ventricular (LV) remodelling in patients with heart failure. "

01/01/2003 - "Only three cholesterol-reducing agents have demonstrated their ability to reduce the incidence of cardiovascular death in long-term follow-up randomised trials among patients with atherosclerosis. "
01/01/2016 - "Antioxidants are reducing agents which inhibit the oxidation of other molecules and can be used not only to prevent but also to treat health complications of MS and atherosclerosis. "
07/17/1961 - "[Action of some cholesterol-reducing agents in atherosclerosis in advanced old age]."
01/01/2015 - "While it may not be an easy proposition to dismantle statins from their current position as a cholesterol reducing agent and as a drug to reduce coronary and cerebro-vascular atherosclerosis, our improved understanding of the disease and appropriate harnessing of resources using sound and robust technology could make rapid in-roads in our pursuit of the ideal anti-dyslipidemic drug. "
03/01/1987 - "Protection against atherogenesis with the polymer drag-reducing agent Separan AP-30."

05/01/1988 - "Hemodynamic parameters associated with chronic exertional angina pectoris in patients with angiographically significant coronary artery disease improved more with a preload reducing agent, like molsidomine."
09/18/2014 - "Previous analyses have suggested that ivabradine, a heart-rate-reducing agent, may improve outcomes in patients with stable coronary artery disease, left ventricular dysfunction, and a heart rate of 70 beats per minute or more. "
12/01/2001 - "The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) is the first coronary heart disease (CHD) primary prevention trial of the cholesterol-reducing agents called "statins" to include women. "
01/01/2021 - "Ivabradine is a selective heart rate-reducing agent, an inhibitor of hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels, currently approved for treatment of coronary artery disease and chronic heart failure. "
01/01/2019 - "These include: (1) the successful development of heart rate-reducing agents, such as ivabradine, able to control cardiac rhythm and useful in the treatment of diseases such as coronary artery disease, heart failure and tachyarrhythmias; (2) the understanding of the genetic basis of disorders of cardiac rhythm caused by HCN channelopathies; (3) the design of strategies to implement biological pacemakers based on transfer of HCN channels or of stem cell-derived pacemaker cells expressing If, with the ultimate goal to replace electronic devices. "

06/01/1979 - "In addition to its present indications in the treatment of angina pectoris and arrhythmias, the drug might be very useful as an afterload-reducing agent."
05/01/1988 - "Hemodynamic parameters associated with chronic exertional angina pectoris in patients with angiographically significant coronary artery disease improved more with a preload reducing agent, like molsidomine."

12/01/2023 - "Our results clearly suggest that this inhibitor could be a promising agent reducing CRC tumor progression when administered either alone or in combination with standard treatment in CRC patients."
08/08/2023 - "Their synthesis using Averrhoa bilimbi leaf extract as a reducing agent was proven to be successful, resulting in spherical and monodispersed nanoparticles that exhibit effective cytotoxicity against cancer cells."
01/01/2023 - "To prevent ROS from harming tumor cells, tumor cells can increase the production of reducing agents to counteract excessive ROS. "
12/01/2020 - "As a result, many medical practitioners are reductant to use deep learning as the only tool for critical machine learning application, such as aiding tool for cancer diagnosis. "
01/01/2019 - "Importantly, we demonstrated that the scFvGPIIb/IIIa-MMAE displays marked efficacy as an anti-cancer agent, reducing tumor growth and preventing metastatic disease, without any discernible toxic effects. "